American College of Nuclear Medicine Names Alan Klitzke as 47th President
Alan Klitzke, MD has been named the 2018 president of the American College of Nuclear Medicine.
Alan Klitzke, MD
Alan Klitzke, MD
Alan Klitzke, MD has been named the 2018 president of the American College of Nuclear Medicine (ACNM). He will serve a 1-year term with the goal of advancing the field both nationally and internationally.
ACNM is an international organization composed of physicians and scientists involved in both clinical and scientific practice of nuclear medicine. Klitzke plans to develop a new collaboration agreement between the ACNM and the British Nuclear Medicine Society during his time as president.
Klitzke is an associate professor of oncology in the Department of Diagnostic Radiology at Roswell Park Comprehensive Cancer Center, as well as an assistant professor of radiology and assistant professor of nuclear medicine at the Jacobs School of Medicine and Biomedical Sciences at the University of Buffalo.
He specializes in whole-body PET/CT imaging, CT guided biopsy procedures, CT, MRI, and Ultrasound imaging of the thorax, abdomen, and pelvis. He works closely with a team of doctors to ensure all patients are diagnosed and treated properly at Roswell Park Comprehensive Cancer Center as a diagnostic physician.
Roswell Park Comprehensive Cancer Center is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. It is a community of doctors driven to eliminate cancer by unlocking new discoveries through personalized approaches.
Prior to his installment as the president of ACNM at the annual awards ceremony, Klitzke was recognized for his service in nuclear medicine by the former president. He was 1 of 3 recipients for the President’s Award.
“As the president of ACNM, I will work to continue the advancement of not only this field, but the organization as well,” Klitzke said in a statement. “I am humbled and honored to take on this leadership role. I look forward to what we will accomplish in this year ahead.”
The ACNM can look forward to new advancements in diagnostic and therapeutic medicine and international collaborations under Klitzke’s 1-year term as president.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
November 13th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.
Read More
